 |
|
|
 |
Global Health Research Plan for HIV/AIDS, Malaria, and Tuberculosis
During an address this morning to international infectious disease specialists, National Institute of Allergy and Infectious Diseases (NIAID) Director Anthony S. Fauci, M.D., unveiled the Institute's global plan to combat three leading infectious killers. The NIAID Global Health Research Plan for HIV/AIDS, Malaria and Tuberculosis provides short-, mid-, and long-term objectives for battling these diseases by building on the Institute's strong foundation in global infectious disease research. You may read the full report in today's issue of Vidyya. more
|
|
Hepatitis C Risk Not Limited To Injection Drug Users
A study in New York City has found a higher than expected prevalence of hepatitis C infection among non-injecting drug users. In this study, as many as 17 percent of the subjects who denied a history of injection drug use were found to be infected, compared to a 2 percent infection rate in the general population. Among women from one of the study sites in East Harlem who reported use of non-injection heroin, the rate of infection was as high as 26 percent. more
|
|
|
|
Information For Professionals - At-A-Glance: Recommended Infection Control Practices For Hemodialysis Units
These At-A-Glance recommendations replace previous recommendations for the prevention of bloodborne virus infections in hemodialysis centers and provide additional recommendations for the prevention of bacterial infections in this setting. The recommendations are intended to serve as a resource for health-care professionals, public health officials, and organizations involved in the care of patients receiving hemodialysis. more
|
|
FDA Approves Axert For Treatment Of Migraine
Pharmacia Corporation announced today that the US Food and Drug Administration (FDA) has approved Axert(TM) (almotriptan malate tablets) for the acute treatment of migraine with or without aura in adults. more
|
|
Metabolife Diet & Energy Bars Recalled Due To Excess Vitamin A
Metabolife International has issued a voluntary recall of all of its Metabolife Diet & Energy Bars manufactured through May 4, 2001, because the products contain a significantly higher-than- labeled level of vitamin A (approximately 32,500 IU per bar) due to an error by the contract manufacturer, MLO Products, Inc. more
|
|
|
